Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Return on Sales (2016 - 2025)

Historic Return on Sales for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to 4.92%.

  • Ocular Therapeutix's Return on Sales fell 20600.0% to 4.92% in Q4 2025 from the same period last year, while for Dec 2025 it was 5.07%, marking a year-over-year decrease of 24800.0%. This contributed to the annual value of 5.07% for FY2025, which is 24800.0% down from last year.
  • Latest data reveals that Ocular Therapeutix reported Return on Sales of 4.92% as of Q4 2025, which was down 20600.0% from 4.67% recorded in Q3 2025.
  • Over the past 5 years, Ocular Therapeutix's Return on Sales peaked at 1.42% during Q3 2023, and registered a low of 5.9% during Q1 2025.
  • For the 5-year period, Ocular Therapeutix's Return on Sales averaged around 2.59%, with its median value being 1.9% (2021).
  • As far as peak fluctuations go, Ocular Therapeutix's Return on Sales skyrocketed by 106000bps in 2021, and later tumbled by -37500bps in 2025.
  • Over the past 5 years, Ocular Therapeutix's Return on Sales (Quarter) stood at 1.6% in 2021, then grew by 8bps to 1.48% in 2022, then dropped by -4bps to 1.54% in 2023, then plummeted by -87bps to 2.87% in 2024, then tumbled by -72bps to 4.92% in 2025.
  • Its Return on Sales stands at 4.92% for Q4 2025, versus 4.67% for Q3 2025 and 4.99% for Q2 2025.